SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Renin-Angiotensin-Aldosterone System
This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Sica, D. A
Right arrow Articles by Gehr, T. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sica, D. A
Right arrow Articles by Gehr, T. W.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Reviews

Review: The pharmacokinetics and pharmacodynamics of angiotensin-receptor blockers in end-stage renal disease

Domenic A Sica

Section of Clinical Pharmacology and Hypertension, dsica@ hsc.vcu.edu

Todd WB Gehr

Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, Virginia, USA

Angiotensin-converting enzyme (ACE) inhibitors and more recently angiotensin-receptor blockers (ARBs) have become popular therapies in the end-stage renal disease (ESRD) patient. The ability of either of these drug classes to reduce blood pressure in the ESRD patient is well accepted; however, there is considerably less information available to guide the clinician in the safe and effective use of these drugs in the ESRD patient with congestive heart failure and/or coronary artery disease. Head-to-head studies in the ESRD patient are lacking for both drug classes. Several pharmacokinetic factors can influence the selection of these drugs, including dialysability and the propensity for systemic accumulation. ACE inhibitors (ACE-Is) and ARBs are recognised as having a range of nonpressor effects that are pertinent to patients with ESRD. Such effects include their ability to decrease both thirst drive and erythropoiesis. These drug classes, though, are distinguishable by the unique adverse effect profile for ACE-Is. As is the case in patients without renal failure, ESRD patients can experience cough and, less frequently, angioneurotic oedema with ACE-Is. In the ESRD population, so-called anaphylactoid dialyser reactions can occur in conjunction with ACE-I use. The use of a drug from within the ARB class carries both less risk and permits a compound with a preferred pharmacokinetic profile — limited dialysability and minimal systemic accumulation — to be administered. These attributes would favour the increased use of ARBs in this population.

Key Words: ACE inhibitors • angiotensin-receptor blockers • anaemia • thirst • congestive heart failure • hypertension • haemodialysis • pharmacokinetics

References

  • US Renal Data System: USRDS 2000 Annual Data Report. The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease, Bethesda, MD, 2000.
  • Mailloux LU, Levey AS Hypertension in patients with chronic renal disease. Am J Kidney Dis 1998;32(suppl 3):S120-S141.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Rahman M., Fu P., Sehgal AR, Smith MC Interdialytic weight gain, compliance with dialysis regimen, and age are independent predictors of blood pressure in hemodialysis patients. Am J Kidney Dis 2000;35:257-65.[Web of Science][Medline] [Order article via Infotrieve]
  • Salem MM Hypertension in the hemodialysis population: A survey of 649 patients. Am J Kidney Dis 1995;26:461-8.[Web of Science][Medline] [Order article via Infotrieve]
  • Cheigh JS, Milite C., Sullivan JF et al. Hypertension is not adequately controlled in hemodialysis patients. Am J Kidney Dis 1992;19:453-9.[Web of Science][Medline] [Order article via Infotrieve]
  • Foley RN, Parfrey PS, Harnett JD et al. Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease. Kidney Int 1996;49:1379-85.[Web of Science][Medline] [Order article via Infotrieve]
  • Longenecker JC, Coresh J., Powe NR et al.Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: The CHOICE Study. J Am Soc Nephrol 2002;13:1918-27.[Abstract/Free Full Text]
  • Sica DA, Gehr TW, Fernandez A. Risk-benefit ratio of angiotensin antagonists versus ACE inhibitors in end-stage renal disease. Drug Saf 2000;22:350-60.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Toto R., Shultz P., Jaij L. et al. Efficacy and tolerability of losartan in hypertensive patients with renal impairment. Hypertension 1998;31:684-91.[Abstract/Free Full Text]
  • Cooper M.,Anzalone D.,Townes L. et al. Safety and efficacy of irbesartan in patients with hypertension and renal insufficiency. Am J Hypertens 1998;11:102A(abstract).
  • Pedro AA, Gehr TW, Brophy DF, Sica DA The pharmacokinetics and pharmacodynamics of losartan in continuous ambulatory peritoneal dialysis.J Clin Pharmacol 2000;40:389-95.[Abstract]
  • Saracho R., Martin-Malo A., Martinez I. et al. Evaluation of the losartan in hemodialysis (ELHE) study. Kidney Inter 1998;54(suppl 68):S125-S129.[CrossRef]
  • Tepel M., van der Giet M., Zidek W. Efficacy and tolerability of angiotensin II type 1 receptor antagonists in dialysis patients using AN69 dialysis membranes. Kidney Blood Press Res 2001; 24:71-4.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Cice G., Ferrara L.,Tagliamonte E. et al. Angiotensin-II receptor inhibitors in hemodialysed uremia patients with arterial hypertension: candesartan cilexitil versus losartan. Cardiologia 1999;44:1071-6.[Medline] [Order article via Infotrieve]
  • Agarwal R., Lewis R., Davis JL, Becker B. Lisinopril therapy for hemodialysis hypertension: hemodynamic and endocrine responses. Am J Kidney Dis 2001;38:1245-50.[Web of Science][Medline] [Order article via Infotrieve]
  • Sica DA, Halstenson CE, Gehr TW, Keane WF Pharmacokinetics and blood pressure response of losartan in end-stage renal disease. Clin Pharmacokinet 2000;38:519-26. 17. Saracho R., Martin-Malo A., Martinez I. et al. Evaluation of the Losartan in Hemodialysis (ELHE) Study. Kidney Int 1998;68: S125-S129.
  • Sica DA, Marino MR, Hammett JL et al. The pharmacokinetics of irbesartan in renal failure and maintenance hemodialysis. Clin Pharmacol Ther 1997;62:610-18.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Kovacs SJ,Tenero DM, Martin DE et al. Pharmacokinetics and protein binding of eprosartan in hemodialysis-dependent patients with end-stage renal disease. Pharmacotherapy 1999;19:612-19.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • de Zeeuw D., Remuzzi G., Kirch W. The pharmacokinetics of candesartan cilexitil in patients with renal or hepatic impairment. J Human Hypertension 1997;11(suppl 2):S37-S42.[Web of Science][Medline] [Order article via Infotrieve]
  • Pfister M., Schaedeli F., Frey FJ, Uehlinger DE Pharmacokinetics and haemodynamics of candesartan cilexetil in hypertensive patients on regular haemodialysis. Br J Clin Pharmacol 1999;47:645-51.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Stangier J., Su CA, Brickl R., Franke H. Pharmacokinetics of single-dose telmisartan 120 mg given during and between hemodialysis in subjects with severe renal insufficiency: comparison with healthy volunteers. J Clin Pharmacol 2000;40: 1365-72.[Abstract]
  • Buter H., Navis GY,Woittiez AJ et al. Pharmacokinetics and pharmacodynamics of candesartan cilexetil in patients with normal to severely impaired renal function. Eur J Clin Pharmacol 1999;54:953-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Martin DE, Chapelsky MC, Ilson B. et al. Pharmacokinetics and protein binding of eprosartan in healthy volunteers and in patients with varying degrees of renal impairment. J Clin Pharmacol 1998;38:129-37.[Abstract]
  • Sica DA, Shaw WC, Lo MW et al.The pharmacokinetics of losartan in renal insufficiency. J Hypertension 1995;13(suppl 1):S49-S52.
  • Prasad P., Mangat S., Choi L. et al. Effect of renal function on the pharmacokinetics of valsartan. Clin Drug Invest 1997;13: 207-14.
  • Leidigi MF, Delles C., Kuchenbecker C. et al. Pharmacokinetics of valsartan in hypertensive patients on long-term hemodialysis. Clin Drug Invest 2001;21:59-66.[CrossRef]
  • von Bergmann K., Laeis P., Puchler K. et al. Olmesartan medoxomil: influence of age, renal and hepatic function on the pharmacokinetics of olmesartan medoxomil. J Hypertens 2001;19(suppl 1):S33-S40.[Web of Science]
  • Choudhury D. ACE-inhibitors prolong PTFE graft survival in hemodialysis patients. J Am Soc Nephrol 2000;11:182A (abstract).
  • Sone M. Angiotensin II inhibition prevents the occlusion of arterio-venous fistula in hemodialysis patients:A case-control study. J Am Soc Nephrol 2000;11:197A (abstract).[CrossRef]
  • Gradzki R., Dhingra RK, Port FK et al. Use of ACE inhibitors is associated with prolonged survival of arteriovenous grafts. Am J Kidney Dis 2001;38:1240-4.[Web of Science][Medline] [Order article via Infotrieve]
  • Swedberg SH, Brown BG, Sigley R. et al. Intimal fibromuscular hyperplasia at the venous anastomosis of PTFE grafts in hemodialysis patients. Clinical, immunocytochemical, light and electron microscopic assessment. Circulation 1989;80:1726-36.
  • Daemen Mjap, Lombardi DM, Bosman FT, Schwartz SM Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ Res 1991;68:450-6.[Abstract/Free Full Text]
  • Parfrey PS, Foley RN, Harnett JD et al. Outcome and risk factors for left ventricular disorders in chronic uraemia. Nephrol Dial Transplant 1996;11:1277-85.[Abstract/Free Full Text]
  • Cannella G., LaCanna G., Sandrini M. et al. Reversal of left ventricular hypertrophy following recombinant human erythropoietin treatment of anaemic dialysed uraemic patients. Nephrol Dial Transplant 1991;6:31-7.[Abstract/Free Full Text]
  • Cannella G., Paoletti E., Delfino R. et al. Regression of left ventricular hypertrophy in hypertensive dialyzed uremic patients on long-term antihypertensive therapy. Kidney Int 1993;44:881-6.[Web of Science][Medline] [Order article via Infotrieve]
  • Cannella G., Paoletti E., Barocci S. et al. Angiotensin-converting enzyme gene polymorphism and reversibility of uremic left ventricular hypertrophy following long-term antihypertensive therapy. Kidney Int 1998;54:618-26.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • London GM, Pannier B., Guerin AP et al. Cardiac hypertrophy, aortic compliance, peripheral resistance and wave reflection in end-stage renal disease. Comparative effects of ACE inhibition and calcium channel blockade. Circulation 1994;90: 2786-96.[Abstract/Free Full Text]
  • Cannella G., Paoletti E., Delfino R. et al. Prolonged therapy with ACE inhibitors induces a regression of left ventricular hypertrophy of dialyzed uremic patients independently from hypotensive effects. Am J Kidney Dis 1997;30:659-64.[Web of Science][Medline] [Order article via Infotrieve]
  • Paoletti E., Cassottana P., Bellino D. et al. Left ventricular geometry and adverse cardiovascular events in chronic hemodialysis patients on prolonged therapy with ACE inhibitors. Am J Kidney Dis 2002;40:728-36.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Shibasaki Y., Masaki H., Nishiue T. et al. Angiotensin II Type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease. Nephron 2002;90:256-61.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • NiuT., Chen X., Xu X. Angiotensin converting enzyme gene insertion/deletion polymorphism and cardiovascular disease: therapeutic implications. Drugs 2002;62:977-93.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Osono E., Kurihara S., Hayama N. et al. Insertion/deletion polymorphism in intron 16 of the ACE gene and left ventricular hypertrophy in patients with end-stage renal disease. Am J Kidney Dis 1998;32:725-30.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Nagahara T., Ishigami T., Sano T. et al.Angiotensin-converting enzyme gene insertion/deletion polymorphism and left ventricular hypertrophy in hemodialysis patients. Jpn Heart J 1997;38:821-30.[Medline] [Order article via Infotrieve]
  • Foley RN, Herzog CA, Collins AJ Blood pressure and long-term mortality in United States hemodialysis patients: USRDS Waves 3 and 4 Study. Kidney Int 2002;62:1784-90.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Efrati S., Zaidenstein R., Dishy V. et al. ACE inhibitors and survival of hemodialysis patients. Am J Kidney Dis 2002;40:1023-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Horl WH ACE inhibitors in hemodialysis patients: Does survival improve? Am J Kidney Dis 2002;40:1100-02.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Guerin AP, Blacher J., Pannier B. et al. Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. Circulation 2001;103:987-92.[Abstract/Free Full Text]
  • Kestenbaum B., Gillen DL, Sherrard DJ et al. Calcium channel blocker use and mortality among patients with end-stage renal disease. Kidney Int 2002;61:2157-64.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Cice G., Ferrara L., Di Benedetto A. et al. Dilated cardiomyopathy in dialysis patients--beneficial effects of carvedilol: a double-blind, placebo-controlled trial. J Am Coll Cardiol 2001; 37:407-11.[Abstract/Free Full Text]
  • McCullough P., Sandberg KR, Yee J., Hudson MP Mortality benefit of angiotensin-converting enzyme inhibitors after cardiac events in patients with end-stage renal disease. JRAAS 2002;3:188-91.[Medline] [Order article via Infotrieve]
  • Van Veldhuisen DJ, Genth-Zotz S., Brouwer J. et al. High versus low-dose ACE inhibition in chronic heart failure. A double-blind, placebo-controlled study of imidapril. J Am Coll Cardiol 1998;32:1811-18.[Abstract/Free Full Text]
  • Massie BM, Armstrong PW, Cleland JG et al. Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS trial. The Assessment of Treatment with Lisinopril and Survival. Arch Intern Med 2001;161:165-71.[Abstract/Free Full Text]
  • Graziani G., Badalamenti S., Del Bo A. et al.Abnormal hemodynamics and elevated angiotensin-II plasma levels in polydipsic patients on regular hemodialysis treatment. Kidney Int 1993;44:107-14.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Rogers PW, Kurtzman NA Renal failure, uncontrollable thirst, and hypereninemia. Cessation of thirst with bilateral nephrectomy. JAMA 1973;225:1236-8.[Abstract/Free Full Text]
  • Yamamoto T. Shimizu M., Morioka M. et al. Role of angiotensin II in the pathogenesis of hyperdipsia in chronic renal failure. JAMA 1986;256:604-08.[Abstract/Free Full Text]
  • Oldenburg B., MacDonald GJ, Shelley S. Controlled trial of enalapril in patients with chronic fluid overload undergoing dialysis. BMJ 1988;296:1089-91.[Abstract/Free Full Text]
  • Bastani B., Redington J. Lack of efficacy of angiotensin converting enzyme inhibitors in reducing interdialytic weight gain. Am J Kid Dis 1994;24:907-11.[Web of Science][Medline] [Order article via Infotrieve]
  • Kuriyama S., Tomonari H., Sakai O. Effect of cilazapril on hyperdipsia in hemodialyzed patients.Blood Purif 1996;14:35-41. 60. Hamad A., Khosrovaneh A., Gupta S. et al. Lack of effect of long-term use of angiotensin-converting enzyme inhibitors by hemodialysis patients on thirst and fluid weight gain. Ren Fail 2002;24:461-6.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Shimada N., Hayashi K., Sak S. et al. Does angiotensin II receptor antagonist losartan suppress drinking behavior in hemodialysis patients? Ren Fail 2001;23:753-5.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Hirakata H., Onoyama K., Iseki K. et al.Worsening of anemia by long-term use of captopril in hemodialysis patients. Am J Nephrol 1984;4:355-60.[Web of Science][Medline] [Order article via Infotrieve]
  • Hirakata H., Onoyama K., Hori K. et al. Participation of the renin-angiotensin system in the captopril-induced worsening of anemia in chronic hemodialysis patients. Clin Nephrol 1986; 26:27-32.[Web of Science][Medline] [Order article via Infotrieve]
  • Yoshida A., Morozumi K., Suganuma T. et al. Angiotensin-converting enzyme inhibitor and anemia in a patient undergoing hemodialysis. Nephron 1991;59:334-5.[Web of Science][Medline] [Order article via Infotrieve]
  • Onoyama K., Sanai T., Motomura K. et al. Worsening of anemia by angiotensin-converting enzyme inhibitors and its prevention by antiestrogenic steroids in chronic hemodialysis patients. J Cardiovasc Pharmacol 1989;13(suppl 3):S27-S30.
  • Thervet E., Legendre C., Debure A. et al. Angiotensin-converting enzyme inhibitors have been reported to induce or worsen anemia in patients on hemodialysis (letter). Am J Kid Dis 1991;18:282-3.[Medline] [Order article via Infotrieve]
  • Miranda B., Selgas R., Oliet A. et al.Treatment with converting enzyme inhibitors can contribute to anemia in CAPD patients. Kidney Int 1990;37:1614.
  • Gould AB, Goodman SA, de Wolf R. et al. Interrelation of the renin system and erythropoietin in rats. J Lab Clin Med 1980; 96:523-34.[Web of Science][Medline] [Order article via Infotrieve]
  • Matsumura M., Nomura H., Koni I., Mabuschi H.Angiotensin-converting enzyme inhibitors are associated with the need for increased recombinant human erythropoietin maintenance doses in hemodialysis patients. Risks of Cardiac Disease in Dialysis Patients Study Group. Nephron 1997;77:164-8.[Web of Science][Medline] [Order article via Infotrieve]
  • Albitar S., Genin R., Fen-Chong M. et al. High dose enalapril impairs the response to erythropoietin treatment in hemodialysis patients. Nephrol Dial Transplant 1998;13:1206-10.[Abstract/Free Full Text]
  • Charytan C., Goldfarb-Rumyantzev A., Wang YF et al. Effect of angiotensin-converting enzyme inhibitors on response to erythropoietin therapy in chronic dialysis patients. Am J Nephrol 1998;18:627-30.
  • Schwenk MH, Jumani AQ, Rosenberg CR et al. Potential angiotensin-converting enzyme inhibitor-epoetin alfa interaction in patients receiving chronic hemodialysis. Pharmacotherapy 1998;18:627-30.[Web of Science][Medline] [Order article via Infotrieve]
  • Morrone LF, Di Paolo S., Logoluso F. et al. Interference of angiotensin-converting enzyme inhibitors on erythropoiesis on kidney transplant recipients: Role of growth factors and cytokines. Transplantation 1997:64:913-18.[CrossRef][Medline] [Order article via Infotrieve]
  • Constantinescu CS, Goodman DB, Ventura ES Captopril and lisinopril suppress production of interleukin-12 by human peripheral blood mononuclear cells. Immunol Lett 1998; 62:25-31.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Azizi M., Rousseau A., Ezan E. et al. Acute angiotensin-converting enzyme inhibition increases the plasma levels of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline. J Clin Invest 1996;97:839-44.[Web of Science][Medline] [Order article via Infotrieve]
  • LeMeur YL, Lorgeot V., Comte L. et al. Plasma levels and metabolism of AcSDKP in patients with chronic renal failure: relationship with erythropoietin requirements. Am J Kid Dis 2001;38:510-17.[Web of Science][Medline] [Order article via Infotrieve]
  • Hortal L., Fernandez A., Vega A. et al. Losartan versus ramipril in the treatment of postrenal transplant erythropoiesis. Trans Proceed 1998;30:2127-8.[CrossRef]
  • Horn S., Holzer H., Horina J. Losartan and renal transplantation.Lancet 1998;351:111.[Medline] [Order article via Infotrieve]
  • Schwarzbeck A., Wittenmeier KW, Hallfritzsch U.Anemia in dialysis patients as a side effect of sartanes. Lancet 1998; 352:286.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Lang SM, Schiffl H. Losartan and anemia of end-stage renal failure. Lancet 1998;352:1708.[Medline] [Order article via Infotrieve]
  • Chew CG,Weise MD, Disney AP The effect of angiotensin II receptor antagonist on the exogenous erythropoietin requirement of haemodialysis patients. Nephrol Dial Transplant 1999; 14:2047-9.[Free Full Text]
  • Schiffl H., Lang SM Angiotensin-converting enzyme inhibitors but not angiotensin II AT1 receptor antagonists affect erythropoiesis in patients with anemia on end-stage renal disease.Nephron 1999;81:106-08.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Kato A.,TakitaT., Mitsuyoshi F. et al. No effect of losartan on response to erythropoietin therapy in patients undergoing hemodialysis? Nephron 2000:86:538-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Pylypchuk GB ACE inhibitor versus angiotensin II blocker induced cough and angioedema. Ann Pharmacother 1998;32: 1060-6.[Abstract]
  • Benz J., Oshrain C., Henry D. et al. Valsartan. A new angiotensin II receptor antagonist: a double-blind study comparing the incidence of cough with lisinopril and hydrochlorothiazide. J Clin Pharmacol 1997;37:101-07.[Abstract]
  • Larochelle P., Flack JM, Marbury TC et al. Effects and tolerability of irbesartan versus enalapril in patients with severe hypertension. Am J Cardiol 1997;80:1613-15.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Acker CG, Greenberg A. Angioedema induced by the angiotensin II blocker losartan. N Engl J Med 1995;333:1572 (letter).[Free Full Text]
  • Boxer M. Accupril and Cozaar-induced angioedema in the same patient. J Allergy Clin Immunol 1996;98:471(letter).[Web of Science][Medline] [Order article via Infotrieve]
  • Sharma PK, Yium JJ Angioedema associated with angiotensin II receptor antagonist losartan. South Med J 1997; 90:552-3.[Web of Science][Medline] [Order article via Infotrieve]
  • van Rijnsoever EW, Kwee-Zuiderwijk WJ, Feenstra J. Angioneurotic edema attributed to the use of losartan. Arch Intern Med 1998;158:2063-5.[Abstract/Free Full Text]
  • Fuchs SA, Koopmans RP, Guchellaar HJ Are angiotensin-II receptor antagonists safe in patients with previous angiotensin-converting enzyme inhibitor-induced angioedema? Hypertension 2001;37:e1(letter).[Medline] [Order article via Infotrieve]
  • Chiu AG, Krowiak EJ, Deeb ZE Angioedema associated with angiotensin II receptor antagonists: challenging our knowledge of angioedema and its etiology. Laryngoscope 2001;111:1729-31.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Warner KK, Visconti JA, Tschampel MM Angiotensin II receptor blockers in patients with ACE inhibitor-induced angioedema.Ann Pharmacother 2000;34:526-8.[Abstract]
  • Dahlof B., Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Dickstein K., Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002;360:752-60.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Sica DA, Black HR Current concepts of pharmacotherapy in hypertension: ACE inhibitor-related angioedema: can angiotensin-receptor blockers be safely used? J Clin Hypertens (Greenwich) 2002;4:375-80.[CrossRef]
  • Tielemans C., Madhoun P., Lenaers M. et al. Anaphylactoid reactions during hemodialysis on AN69 membranes in patients receiving ACE inhibitors. Kidney Int 1990;38:982-4.[Web of Science][Medline] [Order article via Infotrieve]
  • Verresen L., Fink E., Lemke HD, Vanrenterghem Y. Bradykinin is a mediator of anaphylactoid reactions during hemodialysis with AN69 membranes. Kidney Int 1994;45:1497-503.[Web of Science][Medline] [Order article via Infotrieve]
  • Brunet P., Jaber K., BerlandY. et al.Anaphylactoid reactions during hemodialysis and hemofiltration: role of associated AN69 membrane and angiotensin I-converting enzyme inhibitors. Am J Kid Dis 1992;19:444-7.[Web of Science][Medline] [Order article via Infotrieve]
  • Petrie JJB, Campbell Y., Hawley CM et al. Anaphylactoid reactions in patients on haemofiltration with AN69 membranes whilst receiving ACE inhibitors. Clin Nephrol 1991;36:264-5. 101. Parnes EL, Shapiro WB Anaphylactoid reactions in hemodialysis patients treated with the AN69 membrane. Kidney Int 1991;40:1148-52.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Pegues DA, Beck-Sague CM, Woolen SW et al. Anaphylactoid reactions associated with reuse of follow-fiber hemodialyzers and ACE inhibitors. Kidney Int 1992;42:1232-7.[Web of Science][Medline] [Order article via Infotrieve]
  • Daguirdas JT, Ing TS, Roxe DM et al. Severe anaphylactoid reactions to cuprammonium cellulose hemodialyzers. Arch Intern Med 1985;145:489-94.[Abstract/Free Full Text]
  • Krieter D., Grude M., Lemke HD et al.Anaphylactoid reactions during hemodialysis in sheep are ACE inhibitor dose-dependent and mediated by bradykinin. Kidney Int 1998;53: 1026-35.[Web of Science][Medline] [Order article via Infotrieve]
  • Blais C.Jr, Marc-Aurele, J., Simmons WH et al. Des-Arg9 bradykinin metabolism in patients who presented hypersensitivity reactions during hemodialysis: role of serum ACE and aminopeptidase P. Peptides 1999;20:421-30.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Tepel M., van der Giet M., Zidek W. Efficacy and tolerability of angiotensin II type 1 receptor antagonists in dialysis patients using AN69 membranes.Kidney Blood Press Res 2001;24:71-4.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • John B.,Anijeet HK,Ahmad R. Anaphylactic reaction during haemodialysis on AN69 membrane in a patient receiving angiotensin II receptor antagonist. Nephrol Dial Transplant 2001;16:1955-6.[Free Full Text]
  • Bakris GL, Siomos M., Richardson D. et al. ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group. Kidney Int 2000;58:2084-92.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Knoll GA, Sahgal A., Nair RC et al. Renin-angiotensin system blockade and the risk of hyperkalemia in chronic hemodialysis patients. Amer J Med 2002;112:110-14.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Sandle GI, Gaiger E., Tapster S., Goodship TH Evidence for large intestinal control of potassium homoeostasis in uraemic patients undergoing long-term dialysis. Clin Sci (Lond) 1987;73:247-52.[Web of Science][Medline] [Order article via Infotrieve]
  • Sugarman A., Brown RSThe role of aldosterone in potassium tolerance: studies in anephric humans. Kidney Int 1988; 34:397-403.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

Journal of Renin-Angiotensin-Aldosterone System, Vol. 3, No. 4, 247-254 (2002)
DOI: 10.3317/jraas.2002.046
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Sica, D. A
Right arrow Articles by Gehr, T. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sica, D. A
Right arrow Articles by Gehr, T. W.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Advertisement